223) y of laser groups was significantly lower compared to placebo and control groups (p |
224) The end of pain occurred earlier in laser compared to placebo and control groups (p |
225) until exhaustion increased significantly compared to placebo by 4.12 s (95% CI 1.21 |
226) occlusal splint therapy (p < 0.05) compared to placebo group (p < 0.05 |
227) 5) among women who received multivitamins compared to placebo. |
228) photon flux in the BDNF-treated NSC group compared to untreated NSC (p = 0.049) and |
229) ion, and greater functional recovery when compared to untreated NSCs. |
230) f animals injected with BDNF-treated NSCs compared to untreated NSCs. |
231) 3-fold when encapsulated within hydrogels compared to untreated cells. |
232) < 0.001) improved survival (96%) as compared to untreated fish (78% survival). |
233) Compared to Exo(Normoxic) , Exo(Hypoxic) s |
234) f proteins in Exo(Hypoxic) (160 proteins) compared to Exo(Normoxic) (62 proteins), p |
235) nd HSP70), and Annexin II in Exo(Hypoxic) compared to Exo(Normoxic) . |
236) Exo(Hypoxic) have smaller average size as compared to Exo(Normoxic) . |
237) associated with higher swallowing scores compared to all other allele combinations |
238) on coefficient (1.032 × 10-6 cm/h) compared to all other formulations. |
239) Gender-referred children were elevated compared to all other groups for Item 9, a |
240) Survival of group D was prolonged compared to all other groups. |
241) Compared to patients without current hallu |
242) y significantly higher RBC aggregation as compared to patients with moderate preecla |
243) (PSI), and lower A, β and Aβ parameters compared to patients without events [1.84 |
244) inhalational anesthetic requirements when compared to patients without liver disease |
245) Compared to an alternative explanation bas |
246) tion and increased bone regeneration when compared to an anorganic bovine bone xenog |
247) Gambler interview data was compared to an expert 'map' of risk-percep |
248) that ARM-NLC had significantly lower flux compared to drug solution (ARM-SOL). |
249) NLC had better brain targeting efficiency compared to drug solution. |
250) se in drug release and bioavailability as compared to drug suspension from SNEDDS fo |
251) as significantly decreased within group D compared to group B at 36 hours. |
252) ) and B (2.8 ± 1.1 mm; p = 0.03) compared to group C (3.5 ± 1.2 mm). |
253) bone formation in the furcation area when compared to group I (p < 0.0001; p |
254) as obtained with the reformulated drug as compared to pure drug. |
255) 1:9 enhanced solubility nearly 30-fold as compared to pure drug. |
|